2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2024

Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus
Abstract Number: 2025

Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients
Abstract Number: 2026

MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27
Abstract Number: 2027

Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus
Abstract Number: 2028

Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus
Abstract Number: 2029

Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus
Abstract Number: 2030

Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption
Abstract Number: 2031

Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes
Abstract Number: 2032

Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation
Abstract Number: 2033

IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Abstract Number: 2034

Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Abstract Number: 2035

Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell
Abstract Number: 2036

Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus
Abstract Number: 2037

Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity
Abstract Number: 2038

Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].